Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

Authors: Inder Kaul, Sharon Sawchak, Christoph U. Correll, Rishi Kakar, Alan Breier, Haiyuan Zhu, Andrew Miller, Steven M. Paul, Stephen K. Brannan - The Lancet 2023 cited by 223